

# Vijayshree Yadav

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1665658/publications.pdf>

Version: 2024-02-01

46  
papers

2,330  
citations

236833

25  
h-index

276775

41  
g-index

51  
all docs

51  
docs citations

51  
times ranked

3218  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology</i> , 2018, 17, 405-415.	4.9	238
2	The contemporary spectrum of multiple sclerosis misdiagnosis. <i>Neurology</i> , 2016, 87, 1393-1399.	1.5	230
3	Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2018, 379, 846-855.	13.9	201
4	Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis. <i>Neurology</i> , 2014, 82, 1083-1092.	1.5	159
5	Lipoic acid in multiple sclerosis: a pilot study. <i>Multiple Sclerosis Journal</i> , 2005, 11, 159-165.	1.4	133
6	Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 9, 80-90.	0.9	117
7	Lipoic acid in secondary progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e374.	3.1	98
8	Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. <i>Multiple Sclerosis Journal</i> , 2010, 16, 715-723.	1.4	92
9	Perceived Stress in Multiple Sclerosis. <i>Journal of Evidence-Based Complementary &amp; Alternative Medicine</i> , 2014, 19, 104-111.	1.5	89
10	MIF and D-DT are potential disease severity modifiers in male MS subjects. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E8421-E8429.	3.3	83
11	Lipoic Acid Attenuates Inflammation via cAMP and Protein Kinase A Signaling. <i>PLoS ONE</i> , 2010, 5, e13058.	1.1	79
12	Lipoic Acid: A Novel Therapeutic Approach for Multiple Sclerosis and Other Chronic Inflammatory Diseases of the CNS. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2008, 8, 132-142.	0.6	73
13	Complementary and alternative medicine for the treatment of multiple sclerosis. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 381-395.	1.3	72
14	A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005, 11, 552-561.	1.4	67
15	Therapeutic vaccination with a trivalent T cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. <i>Immunology</i> , 2008, 123, 66-78.	2.0	60
16	Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. <i>Contemporary Clinical Trials</i> , 2016, 50, 166-177.	0.8	59
17	Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters. <i>Multiple Sclerosis Journal</i> , 2010, 16, 387-397.	1.4	52
18	Clinical trial of a formal group fatigue program in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 724-732.	1.4	51

#	ARTICLE	IF	CITATIONS
19	Dietary Interventions and Multiple Sclerosis. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 28.	2.0	37
20	Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study. <i>Autoimmune Diseases</i> , 2012, 2012, 1-11.	2.7	33
21	Apical Ballooning Resulting from Limbic Encephalitis. <i>American Journal of Medicine</i> , 2009, 122, 583-586.	0.6	31
22	The Effects of Omega-3 Fatty Acids on Matrix Metalloproteinase-9 Production and Cell Migration in Human Immune Cells: Implications for Multiple Sclerosis. <i>Autoimmune Diseases</i> , 2011, 2011, 1-6.	2.7	30
23	Hypothalamic Dysfunction and Multiple Sclerosis: Implications for Fatigue and Weight Dysregulation. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 98.	2.0	29
24	Use and Self-Reported Benefit of Complementary and Alternative Medicine Among Multiple Sclerosis Patients. <i>International Journal of MS Care</i> , 2006, 8, 5-10.	0.4	28
25	Use of Cannabinoids for Spasticity and Pain Management in MS. <i>Current Treatment Options in Neurology</i> , 2016, 18, 1.	0.7	27
26	A Randomized Pilot Study of Naturopathic Medicine in Multiple Sclerosis. <i>Journal of Alternative and Complementary Medicine</i> , 2008, 14, 489-496.	2.1	26
27	Complementary and Alternative Medical Therapies in Multiple Sclerosis—The American Academy of Neurology Guidelines: A Commentary. <i>Clinical Therapeutics</i> , 2014, 36, 1972-1978.	1.1	20
28	Complementary and alternative medicine: Is there a role in multiple sclerosis?. <i>Current Neurology and Neuroscience Reports</i> , 2006, 6, 259-267.	2.0	17
29	Lipoic Acid Stimulates cAMP Production in Healthy Control and Secondary Progressive MS Subjects. <i>Molecular Neurobiology</i> , 2018, 55, 6037-6049.	1.9	13
30	New Disease-Modifying Therapies and New Challenges for MS. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 489-491.	2.0	12
31	Cross-sectional survey of complementary and alternative medicine used in Oregon and Southwest Washington to treat multiple sclerosis: A 17-Year update. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102041.	0.9	12
32	Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology</i> , 2014, 83, 1484-1486.	1.5	11
33	Treat patients with radiologically isolated syndrome when the MRI brain scan shows dissemination in time: No. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1529-1530.	1.4	10
34	The radiologically isolated syndrome revisited. <i>Neurology</i> , 2011, 76, 680-681.	1.5	9
35	Oral lipoic acid as a treatment for acute optic neuritis: a blinded, placebo controlled randomized trial. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731985019.	0.5	8
36	Alemtuzumab versus interferon beta-1a in early multiple sclerosis. <i>Current Neurology and Neuroscience Reports</i> , 2009, 9, 341-342.	2.0	5

#	ARTICLE	IF	CITATIONS
37	Rituximab for treatment of refractory multiple sclerosis relapses during pregnancy. Multiple Sclerosis Journal, 2021, 27, 1620-1623.	1.4	4
38	A cross-sectional survey of cannabis use by people with MS in Oregon and Southwest Washington. Multiple Sclerosis and Related Disorders, 2021, 55, 103172.	0.9	4
39	Spinal adhesive arachnoiditis mimicking sarcoid myelitis with nodular dural enhancement: A case report. Multiple Sclerosis and Related Disorders, 2020, 44, 102257.	0.9	3
40	Oral Disease-Modifying Therapies for Multiple Sclerosis: Are We There Yet?. Current Neurology and Neuroscience Reports, 2010, 10, 333-335.	2.0	2
41	Demyelinating Disease After Exposure to Tumor Necrosis Factor $\hat{\pm}$ Inhibitors. Journal of Clinical Rheumatology, 2021, Publish Ahead of Print, .	0.5	1
42	Complementary and alternative treatments in multiple sclerosis. , 2011, , 562-573.		0
43	Cognitive Impairment and MS: Searching for Effective Therapies. Current Neurology and Neuroscience Reports, 2011, 11, 451-454.	2.0	0
44	Pearls & Oy-sters: Primary angiitis of the CNS presenting with recurrent intracranial hemorrhage. Neurology, 2020, 94, e992-e995.	1.5	0
45	C-L Case Conference: A 33-year-old Bhutanese Woman with Postpartum Hallucinations. Journal of the Academy of Consultation-Liaison Psychiatry, 2022, , .	0.2	0
46	A Review of Vascular Disease Risk Factors and Multiple Sclerosis. US Endocrinology, 2017, 13, 90.	0.3	0